A226330: SyntekaBio, Inc. - Summary | Jitta

SyntekaBio, Inc.

KOR:A226330

Price
₩1,940.00
Loss Chance
57.9%
1.82JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
195 / 302
1,623 / 2,304
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (37)
Recent Business Performance (65)
Financial Strength (30)
Return to Shareholders (0)
Competitive Advantage (31)
Jitta Signs
SG&A to SalesDecreasing
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 18.91% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.82
100.00%
3.30
330.66%
Health Care Technology
5.45
51.86%
5.39
26.06%
6.43
17.08%
COMPANY DESCRIPTION
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was founded in 2009 and is headquartered in Daejeon, South Korea.